Friday, October 23, 2026

regulation

2 articles

MEXC's Push Into Stocks and Bonds Could Trigger Global Licensing Crackdown

MEXC's Push Into Stocks and Bonds Could Trigger Global Licensing Crackdown

Crypto exchange MEXC is expanding into traditional assets like stocks and bonds, a move regulators worldwide could flag as unlicensed securities activity. A risk assessment dated August 1, 2026 rates the threat as major severity with medium likelihood, and CEO Vugar's public role puts him at direct personal exposure.

LM Salvado•
EU Pushes CSRD Compliance Deadline to 2028, Affecting 40,000 Companies Globally

EU Pushes CSRD Compliance Deadline to 2028, Affecting 40,000 Companies Globally

The European Union postponed mandatory sustainability reporting for 40,000 mid-sized companies from 2026 to 2028 under its Corporate Sustainability Reporting Directive. The delay shifts €20-80 billion in compliance spending and extends uncertainty for multinational firms navigating overlapping disclosure regimes across the EU, US, and international standards.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,475 source documents archived
Query this data → isubstrate.com